
TY  - JOUR
TI  - Monday 29 August 2011
JO  - Journal of Neurochemistry
VL  - 118
IS  - s1
SN  - 0022-3042
UR  - https://doi.org/10.1111/j.1471-4159.2011.07324.x
DO  - doi:10.1111/j.1471-4159.2011.07324.x
SP  - 4
EP  - 83
PY  - 2011
ER  - 

TY  - JOUR
TI  - THURSDAY SESSION
JO  - Journal of Neurochemistry
VL  - 102
IS  - s1
SN  - 0022-3042
UR  - https://doi.org/10.1111/j.0022-3042.2007.04729.x
DO  - doi:10.1111/j.0022-3042.2007.04729.x
SP  - 165
EP  - 235
PY  - 2007
ER  - 

TY  - JOUR
AU  - Judith Radin, M.
AU  - Yu, Ming-Jiun
AU  - Stoedkilde, Lene
AU  - Lance Miller, R.
AU  - Hoffert, Jason D.
AU  - Frokiaer, Jorgen
AU  - Pisitkun, Trairak
AU  - Knepper, Mark A.
TI  - Aquaporin-2 regulation in health and disease
JO  - Veterinary Clinical Pathology
JA  - Vet Clin Pathol
VL  - 41
IS  - 4
SN  - 0275-6382
UR  - https://doi.org/10.1111/j.1939-165x.2012.00488.x
DO  - doi:10.1111/j.1939-165x.2012.00488.x
SP  - 455
EP  - 470
KW  - Exosomes
KW  - polyuria
KW  - syndrome of inappropriate antidiuretic hormone excess
KW  - transcription
KW  - vasopressin
PY  - 2012
AB  - Abstract Aquaporin-2 (AQP2), the vasopressin-regulated water channel of the renal collecting duct, is dysregulated in numerous disorders of water balance in people and animals, including those associated with polyuria (urinary tract obstruction, hypokalemia, inflammation, and lithium toxicity) and with dilutional hyponatremia (syndrome of inappropriate antidiuresis, congestive heart failure, cirrhosis). Normal regulation of AQP2 by vasopressin involves 2 independent regulatory mechanisms: (1) short-term regulation of AQP2 trafficking to and from the apical plasma membrane, and (2) long-term regulation of the total abundance of the AQP2 protein in the cells. Most disorders of water balance are the result of dysregulation of processes that regulate the total abundance of AQP2 in collecting duct cells. In general, the level of AQP2 in a collecting duct cell is determined by a balance between production via translation of AQP2 mRNA and removal via degradation or secretion into the urine in exosomes. AQP2 abundance increases in response to vasopressin chiefly due to increased translation subsequent to increases in AQP2 mRNA. Vasopressin-mediated regulation of AQP2 gene transcription is poorly understood, although several transcription factor-binding elements in the 5? flanking region of the AQP2 gene have been identified, and candidate transcription factors corresponding to these elements have been discovered in proteomics studies. Here, we review progress in this area and discuss elements of vasopressin signaling in the collecting duct that may impinge on regulation of AQP2 in health and in the context of examples of polyuric diseases.
ER  - 

TY  - JOUR
TI  - SIUD Abstracts
JO  - Neurourology and Urodynamics
JA  - Neurourol. Urodynam.
VL  - 35
IS  - S3
SN  - 0733-2467
UR  - https://doi.org/10.1002/nau.23037
DO  - doi:10.1002/nau.23037
SP  - S3
EP  - S68
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Fundamental & Clinical Pharmacology
VL  - 25
IS  - s1
SN  - 0767-3981
UR  - https://doi.org/10.1111/j.1472-8206.2011.00930.x
DO  - doi:10.1111/j.1472-8206.2011.00930.x
SP  - 1
EP  - 111
PY  - 2011
ER  - 

TY  - JOUR
TI  - Poster Session TPS 19-33
JO  - Allergy
JA  - Allergy
VL  - 71
IS  - S102
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.12976
DO  - doi:10.1111/all.12976
SP  - 413
EP  - 504
PY  - 2016
ER  - 

C7  - pp. 1129-1173
TI  - Index
SN  - 9781119188391
UR  - https://doi.org/10.1002/9781119188421.index
DO  - doi:10.1002/9781119188421.index
SP  - 1129-1173
PY  - 2016
ER  - 

TY  - JOUR
TI  - SARS ORAL 2010
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 97
IS  - S6
SN  - 9781119188391
UR  - https://doi.org/10.1002/bjs.7351
DO  - doi:10.1002/bjs.7351
SP  - 7
EP  - 38
PY  - 2010
ER  - 

TY  - JOUR
TI  - Posters: Basic and clinical science posters: Beta-cells and islets
JO  - Diabetic Medicine
VL  - 27
IS  - s1
SN  - 9781119188391
UR  - https://doi.org/10.1111/j.1464-5491.2009.02936.x
DO  - doi:10.1111/j.1464-5491.2009.02936.x
SP  - 37
EP  - 188
PY  - 2010
ER  - 

TY  - JOUR
TI  - X - Late Breaking Abstracts
JO  - Clinical Genetics
VL  - 78
IS  - s1
SN  - 9781119188391
UR  - https://doi.org/10.1111/j.1399-0004.2010.01584.x
DO  - doi:10.1111/j.1399-0004.2010.01584.x
SP  - 112
EP  - 133
PY  - 2010
ER  - 

TY  - JOUR
AU  - Mintz, Rachel L.
AU  - Gao, Madeleine A.
AU  - Lo, Kahmun
AU  - Lao, Yeh-Hsing
AU  - Li, Mingqiang
AU  - Leong, Kam W.
C7  - 1800132
TI  - CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy
JO  - Advanced Biosystems
JA  - Adv. Biosys.
VL  - 2
IS  - 11
SN  - 9781119188391
UR  - https://doi.org/10.1002/adbi.201800132
DO  - doi:10.1002/adbi.201800132
SP  - 1800132
KW  - breast cancer
KW  - CRISPR
KW  - precision medicine
KW  - targeted therapeutics
PY  - 2018
AB  - Abstract Molecularly, breast cancer represents a highly heterogenous family of neoplastic disorders, with substantial interpatient variations regarding genetic mutations, cell composition, transcriptional profiles, and treatment response. Consequently, there is an increasing demand for alternative diagnostic approaches aimed at the molecular annotation of the disease on a patient-by-patient basis and the design of more personalized treatments. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) technology enables the development of such novel approaches. For instance, in diagnostics, the use of the RNA-specific C2c2 system allows ultrasensitive nucleic acid detection and could be used to characterize the mutational repertoire and transcriptional breast cancer signatures. In disease modeling, CRISPR/Cas9 technology can be applied to selectively engineer oncogenes and tumor-suppressor genes involved in disease pathogenesis. In treatment, CRISPR/Cas9 can be used to develop gene-therapy, while its catalytically-dead variant (dCas9) can be applied to reprogram the epigenetic landscape of malignant cells. As immunotherapy becomes increasingly prominent in cancer treatment, CRISPR/Cas9 can engineer the immune cells to redirect them against cancer cells and potentiate antitumor immune responses. In this review, CRISPR strategies for the advancement of breast cancer diagnostics, modeling, and treatment are highlighted, culminating in a perspective on developing a precision medicine-based approach against breast cancer.
ER  - 

TY  - JOUR
TI  - Tuesday, 1 September 2009 - Parallel Sessions 19-36
JO  - Transplant International
VL  - 22
IS  - s2
SN  - 9781119188391
UR  - https://doi.org/10.1111/j.1432-2277.2009.00960.x
DO  - doi:10.1111/j.1432-2277.2009.00960.x
SP  - 45
EP  - 81
PY  - 2009
ER  - 

TY  - JOUR
TI  - 2nd World Parkinson Congress Abstracts
JO  - Movement Disorders
JA  - Mov. Disord.
VL  - 25
IS  - S3
SN  - 9781119188391
UR  - https://doi.org/10.1002/mds.23386
DO  - doi:10.1002/mds.23386
SP  - S569
EP  - S717
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Basic and Applied Pathology
VL  - 2
IS  - s1
SN  - 9781119188391
UR  - https://doi.org/10.1111/j.1755-9294.2009.01059.x
DO  - doi:10.1111/j.1755-9294.2009.01059.x
SP  - A1
EP  - A119
PY  - 2009
ER  - 

TY  - JOUR
TI  - Tuesday 30 August 2011
JO  - Journal of Neurochemistry
VL  - 118
IS  - s1
SN  - 9781119188391
UR  - https://doi.org/10.1111/j.1471-4159.2011.07325.x
DO  - doi:10.1111/j.1471-4159.2011.07325.x
SP  - 84
EP  - 164
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts 1 to 257
JO  - Hepatology
JA  - Hepatology
VL  - 42
IS  - S1
SN  - 9781119188391
UR  - https://doi.org/10.1002/hep.20923
DO  - doi:10.1002/hep.20923
SP  - 196A
EP  - 298A
PY  - 2005
ER  - 

TY  - JOUR
TI  - Invited Speaker Abstracts
JO  - Immunology
JA  - Immunology
VL  - 143
IS  - s2
SN  - 9781119188391
UR  - https://doi.org/10.1111/imm.12404
DO  - doi:10.1111/imm.12404
SP  - 1
EP  - 40
PY  - 2014
ER  - 

TY  - JOUR
TI  - Matrix Biology Europe – July 2018 Meeting Celebrating 50 years of Federation of European Connective Tissue Societies Meetings(organised by the British Society for Matrix Biology and the University of Manchester Wellcome Trust Centre for Cell-Matrix Research)
JO  - International Journal of Experimental Pathology
JA  - Int. J. Exp. Path.
VL  - 99
IS  - 6
SN  - 9781119188391
UR  - https://doi.org/10.1111/iep.12294
DO  - doi:10.1111/iep.12294
SP  - A1
EP  - A69
PY  - 2018
ER  - 

TY  - JOUR
TI  - PUBLICATION
JO  - Hematological Oncology
JA  - Hematol Oncol
VL  - 31
IS  - S1
SN  - 9781119188391
UR  - https://doi.org/10.1002/hon.2059
DO  - doi:10.1002/hon.2059
SP  - 201
EP  - 270
PY  - 2013
ER  - 

TY  - JOUR
AU  - Krämer, Stefanie D.
AU  - Testa, Bernard
TI  - The Biochemistry of Drug Metabolism – An Introduction
JO  - Chemistry & Biodiversity
JA  - Chemistry & Biodiversity
VL  - 6
IS  - 10
SN  - 9781119188391
UR  - https://doi.org/10.1002/cbdv.200900233
DO  - doi:10.1002/cbdv.200900233
SP  - 1477
EP  - 1660
KW  - Drug metabolism
KW  - Enzyme induction
KW  - Enzyme inhibition
KW  - Nuclear receptors
KW  - Ontogeny
PY  - 2009
AB  - Abstract This review on intra-individual factors affecting drug metabolism completes our series on the biochemistry of drug metabolism. The article presents the molecular mechanisms causing intra-individual differences in enzyme expression and activity. They include enzyme induction by transcriptional activation and enzyme inhibition on the protein level. The influencing factors are of physiological, pathological, or external origin. Tissue characteristics and developmental age strongly influence enzyme-expression patterns. Further influencing factors are pregnancy, disease, or biological rhythms. Xenobiotics, drugs, constituents of herbal remedies, food constituents, ethanol, and tobacco can all influence enzyme expression or activity and, hence, affect drug metabolism.
ER  - 
